Texas Medicaid spending on GLP-1 drugs

How much did Texas Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $179.0 million for GLP-1 drugs paid through Texas Medicaid in 2025, across at least 172,353 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 114 rows of 244, so these figures are floors.

Pharmacies were reimbursed at least $54.9 million for GLP-1 drugs paid through Texas Medicaid in 2026 (quarter 1 only, as posted so far), across at least 50,835 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 30 rows of 72, so these figures are floors.

By year and ingredient

2020at least $5,121,463No dataat least $18,405,819at least $8,575,372at least $10,334,021at least $265,461at least $296,418at least $42,998,554
2021at least $11,142,900No dataat least $21,096,432at least $16,398,382at least $8,002,045at least $298,637at least $196,733at least $57,135,129
2022at least $22,939,486No dataat least $20,803,316at least $45,555,902at least $4,662,586at least $284,253$131,319at least $94,376,863
2023at least $61,944,446at least $12,771,150at least $16,471,212at least $52,959,971at least $2,644,692at least $302,470$100,342at least $147,194,283
2024at least $85,029,824at least $29,654,104at least $4,403,627at least $25,411,917at least $1,016,528at least $165,156at least $26,756at least $145,707,912
2025at least $101,930,917at least $54,602,710at least $1,260,801at least $20,894,884at least $204,417$122,334Suppressedat least $179,016,062
2026 (Q1)at least $28,873,232at least $20,278,089at least $200,795at least $5,526,871Suppressed$17,345Suppressedat least $54,896,332

By product, 2025

Ozempic$92,262,94592,3180 of 24
Rybelsusat least $3,637,384at least 2,8744 of 16
Wegovyat least $6,030,588at least 4,63813 of 33
Mounjaroat least $54,232,726at least 48,74440 of 64
Zepboundat least $369,984at least 34814 of 18
Liraglutide (generic name listing)at least $584,031at least 1,3457 of 23
SaxendaSuppressedSuppressed3 of 3
Victozaat least $676,769at least 1,0834 of 12
Trulicityat least $20,894,884at least 20,57818 of 34
Bydureonat least $204,417at least 2751 of 3
ByettaSuppressedSuppressed3 of 3
Exenatide (generic name listing)SuppressedSuppressed3 of 3
Soliqua$122,3341500 of 4
XultophySuppressedSuppressed4 of 4

By quarter, 2025

Q1 2025at least $40,884,160at least 39,56727 of 57
Q2 2025at least $45,516,601at least 43,22324 of 56
Q3 2025at least $44,538,944at least 42,56833 of 64
Q4 2025at least $48,076,357at least 46,99530 of 67

By quarter, 2026 (posted so far)

Q1 2026at least $54,896,332at least 50,83530 of 72

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.